Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

In the past week, a Boston biotech led by longtime industry CEO Harvey Berger said it plans to shut down, while another ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Her name was Martha, and she was one of the few neighbors on the street I didn’t meet. This is something that does haunt me a bit. A missed opportunity to ...

We spoke recently with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the ...

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in ...

I can tell you that VDPHL01 has a unique profile unlike current FDA-approved treatments, which are associated with cardiac ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

In some states, this may even allow the name change to proceed without a hearing. If you cannot reach another parent or guardian for their consent, document your attempts to serve notice so you ...

By phase insights, the phase III segment dominates the U.S. clinical trials market. Phase III clinical trials are characterized by their substantial scale, often engaging a diverse and large cohort of ...